1. Home
  2. MTZ vs UTHR Comparison

MTZ vs UTHR Comparison

Compare MTZ & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MasTec Inc.

MTZ

MasTec Inc.

HOLD

Current Price

$219.26

Market Cap

13.6B

Sector

Industrials

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$489.62

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTZ
UTHR
Founded
1929
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Water Sewer Pipeline Comm & Power Line Construction
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
20.3B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
MTZ
UTHR
Price
$219.26
$489.62
Analyst Decision
Strong Buy
Buy
Analyst Count
20
12
Target Price
$228.89
$495.08
AVG Volume (30 Days)
753.0K
424.3K
Earning Date
10-30-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
270.77
16.08
EPS
4.20
26.38
Revenue
$13,762,473,000.00
$3,128,400,000.00
Revenue This Year
$15.48
$13.64
Revenue Next Year
$10.21
$5.78
P/E Ratio
$52.30
$18.55
Revenue Growth
12.99
13.50
52 Week Low
$99.70
$266.98
52 Week High
$224.03
$492.62

Technical Indicators

Market Signals
Indicator
MTZ
UTHR
Relative Strength Index (RSI) 65.92 68.10
Support Level $207.94 $470.13
Resistance Level $214.00 $492.62
Average True Range (ATR) 8.12 10.72
MACD 2.47 -0.53
Stochastic Oscillator 90.92 89.55

Price Performance

Historical Comparison
MTZ
UTHR

About MTZ MasTec Inc.

MasTec is a leading infrastructure construction company operating mainly in North America across a range of industries. The company's primary activities include engineering, building, installing, maintaining, and upgrading communications, oil and gas, utility, renewable energy, and other infrastructure. MasTec reports its results under five segments: communications; clean energy and infrastructure; oil and gas; power delivery; and other.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: